In a talk at ASCO 2022, Eunice Wang, MD, will present long-term results from a phase 2 trial of crenolanib with chemotherapy for treatment of adults with newly diagnosed FLT3-mutant AML.

“Our results were highly promising, with more than 80% of patients who received the crenolanib chemotherapy combination achieving clinical responses after treatment, and more than half still alive after almost 4 years.”

CHICAGO (PRWEB)
June 06, 2022

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML). Dr. Wang will discuss the findings at the American Society of Clinical Oncology (ASCO) annual meeting 2022, at 11:57 a.m. CDT, in Hall S, room 100a, during the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant oral abstract session (abstract 7007).

In this multicenter Roswell Park-led clinical trial, 44 patients with newly diagnosed FLT3-mutant AML received standard front-line induction chemotherapy with cytarabine for 7 days and daunorubicin or idarubicin for 3 days. Starting on day 9, crenolanib, which is an active inhibitor of FLT3- ITD, TKD and variant AML mutations, was administered three times per day until 3 days before the next chemotherapy treatment. Most patients (75%) had FLT3-ITD mutations, 8 patients (18%) had TKD mutations, and 3 patients (7%) had both ITD and TKD mutations.

After one treatment cycle, 73% of patients experienced clinical responses, and 86% of patients responded to treatment after two cycles. Better responses were noted in younger patients (≤ 60 years) and those with FLT3-ITD mutations.

“Our results were highly promising, with more than 80% of patients who received the crenolanib chemotherapy combination achieving clinical responses after treatment, and more than half still alive after almost 4 years,” says Dr. Wang, principal investigator of the clinical trial and senior author of the study. “We believe that addition of this next-generation FLT3 inhibitor to conventional chemotherapy could significantly improve outcomes and become the new standard of care for patients with FLT3-mutant AML.”

The most common treatment-related adverse events were diarrhea, nausea and febrile neutropenia, and six patients required crenolanib dose reduction during treatment. Approximately 15% of patients experienced disease relapse, but mutational analysis in these patients showed clearance of multiple FLT3 mutations and no new FLT3 clones.

A larger, phase 3 clinical trial (NCT03258931) randomizing patients with newly diagnosed FLT3-mutant AML to receive either crenolanib or midostaurin is underway at 31 sites and currently enrolling patients at Roswell Park.

###

This release is also available at: https://www.roswellpark.org/newsroom/202206-roswell-park-expert-present-effectiveness-new-combination-acute-myeloid-leukemia

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Share article on social media or email:

NCPDP Foundation

SCOTTSDALE, Ariz. (PRWEB)
June 06, 2022

The NCPDP Foundation Board of Trustees announced its second 2022 call for grant proposals that demonstrate the value of NCPDP standards in supporting patient safety, access to care and the expanded role of pharmacists. Grant proposals must meet the grant proposal requirements and be submitted electronically by August 18, 2022, to be considered for the current grant funding cycle.

Research projects must benefit at least one of the NCPDP Foundation strategic initiatives: increasing the role and value of pharmacists; increasing patient access to care; and enhancing patient safety. In addition, research projects must seek to demonstrate and measure how an underutilized NCPDP Standard or a new use for an NCPDP Standard supports the strategic initiative and improves interoperability. Alternatively, the project can demonstrate the need for a new NCPDP standard that supports the initiatives. Descriptions of NCPDP Standards are available on the NCPDP website. Membership in NCPDP is required to access the Standards. The Foundation will consider proposals that broadly support standardization of the exchange of healthcare information and also align with the Foundation’s Vision, Purpose and three strategic initiatives.

Areas of particular interest include demonstrating the value of the Specialty Medication Enrollment Standard; the NCPDP Pharmacy Services Billing Transaction in the Telecommunication Standard; or showing how other NCPDP Standards support value-based arrangements (VBAs), precision medicine, social determinants of health (SDOH), digital therapy (DTx) or the NCPDP National Facilitator Model. While these areas are currently of particular interest, the NCPDP Foundation welcomes and will evaluate other projects that meet the essential criteria.

To submit a grant proposal, complete and submit the Request for Funding form along with supplemental material by August 18, 2022. View Frequently Asked Questions for more information.

About NCPDP Foundation

The NCPDP Foundation is a 501(c)(3) nonprofit charitable organization headquartered in Scottsdale, Arizona and is affiliated with the National Council for Prescription Drug Programs (NCPDP). The NCPDP Foundation was established in December 2012 to support research, education, and charitable involvement within the healthcare industry. For more information, visit http://ncpdpfoundation.org.

###

Share article on social media or email:

“Our continued expansion is positioning us for the future of healthcare and identifying and retaining top leadership is a key priority for the delivery of continued transformation and extraordinary results in the ongoing evolution of our industry.” – Larry Benz, Confluent Health’s CEO

LOUISVILLE, Ky. (PRWEB)
June 06, 2022

Confluent Health is proud to announce the appointment of John Doyle to the position of Chief Financial Officer in response to the company’s continued growth. With over 30 years of healthcare and finance experience, Doyle is a highly experienced financial leader in the healthcare services and managed care industries.

The appointment also sees current CFO, John Thompson (“JT”), named into a newly formed executive leadership role as the Chief Administrative Officer.

In this role, JT will have continued responsibilities leading Confluent Health’s managed support teams, including Human Resources, Recruitment, Information Technology, Real Estate, Risk Management and the Project Management Office on behalf of the Company’s 44 private practice physical and occupational therapy partner companies, higher education company, Evidence in Motion, occupational health company, Fit For Work, and national Independent Provider Association, PTPN, and Confluent Innovations, LLC.

“Confluent Health’s commitment to transforming health care continues to prove wildly successful, resulting in continued growth,” said Larry Benz PT, DPT, OCS, MBA, FAPTA, Confluent Health’s Chief Executive Officer. “Our continued expansion is positioning us for the future of healthcare and identifying and retaining top leadership is a key priority for the delivery of continued transformation and extraordinary results in the ongoing evolution of our industry,” said Benz.

Doyle’s extensive accounting and finance experience is the perfect skillset for continuing the company’s mission of innovating for the future of healthcare. “John’s deep experience in large, multi-site, complex health care companies will be powerful in leading the financial team at Confluent through continued growth,” said Benz.

Prior to his most recent role as the Chief Financial Officer at billion-dollar physician-owned healthcare services organization, Steward Health Care Systems, Doyle held executive leadership positions at IASIS Healthcare Corporation as Chief Financial Officer, Chief Accounting Officer and Treasurer, and Senior Manager positions at Ernst & Young where he specialized in healthcare audit and business advisory services. A proven financial executive, Doyle is eager to call Confluent Health and Louisville his new home.

“I am honored to serve as Confluent Health’s next CFO. It is a privilege to be part of an innovative organization with a relentless commitment to positive, demonstrated industry disruption. I am excited to join at a time of explosive growth for the company, our partners, and employees. I look forward to working with the Confluent Health family on our continued financial and operational transformation,” said Doyle.

Doyle’s arrival comes at an exciting time for the company, in which Confluent Health has been building an Innovation Center focused on radical innovation and positive disruptive solutions for addressing the musculoskeletal spend and inefficient care pathways in the U.S. Current initiatives deliver exclusive access to digital therapeutics, collaborations with Curable, Walmart, and BehaVR, and branded care innovations such as PTNow, mōviMSK, BackNOW.

In addition to Confluent Health’s outpatient physical and occupational therapy clinic footprint which spans 44 company partners, with 525+ outpatient clinics across 29 states, it also houses higher-education company, Evidence in Motion, who offer post-professional training, house the nation’s largest residency and fellowship program, and forge university partnerships in entry-level physical and occupational therapy, and PA programs. Occupational health company, Fit For Work, holds 1,500 workplace safety and injury prevention sites in 48 states, PTPN a national Independent Provider Association, and Confluent Innovations LLC. are also members of the Confluent Health family.

Attracting Doyle to the executive leadership team reaffirms Confluent Health’s commitment to supporting its partners with vigorous financial and administrative resources as well as the company’s commitment to continued growth.

Doyle assumes his role officially on June 15th, 2022, at Confluent Health’s office headquarters in Louisville, KY.

###

About Confluent Health:

Confluent Health is a family of physical and occupational therapy companies. We are transforming health care by strengthening private practices, developing highly effective clinicians, innovating new services and technology to improve the quality of care for patients, and lowering costs via more effective treatment, workplace wellness, and injury prevention. For more information, visit http://www.goconfluent.com or find us on Facebook, LinkedIn, and Twitter at @confluentfamily.

Share article on social media or email:

“It is a privilege to be part of an organization that is committed to investing in the evolution of the healthcare industry, bringing game-changing solutions closer to our partners, patients and providers.” – Brooks Newman, Chief Strategy & Innovation Officer of Confluent Health Innovations

LOUISVILLE, Ky. (PRWEB)
June 06, 2022

Confluent Health is proud to announce the appointment of Brooks Newman to the newly created role as Chief Strategy & Innovation Officer and President of Confluent Health Innovations, LLC. Newman is an accomplished business leader who has been hand-selected to champion strategy and innovation across the organization, driving innovation capabilities and pushing new growth opportunities.

“The Innovation Center was founded with a clear purpose and vision of building future healthcare models that meet people where they are,” said Newman. “It is a privilege to be part of an organization that is committed to investing in the evolution of the healthcare industry, bringing game-changing solutions closer to our partners, patients, and providers.”

Confluent Health’s newly formed Innovation Center, formally known as Confluent Health Innovations, LLC, is comprised of a dedicated portfolio of value-based programs, venture capital investments, digital experiences, and emerging products and services. “By teaming with stakeholders across the enterprise, Confluent Health Innovations will leverage the organization’s unique musculoskeletal channels and capabilities in order to further differentiate the company in the marketplace, provide unique value to customers, and execute on investments that drive top-line growth,” said Newman.

Confluent Health Innovations is committed to positive disruptive solutions for addressing the musculoskeletal spending in the U.S. and curating customer experiences that are seamless, on-demand, and highly enabled by technology, whether they are a patient, an employer, a payer, or a student. Confluent Health’s portfolio companies and customers will receive exclusive access to digital therapeutics, collaborations with the Curable chronic pain app, Walmart Health + Wellness, and BehaVR, and branded care innovations such as the PTNow app, mōviMSK, BackNOW, and The Pain Squad.

Newman previously served as Chief Legal & Compliance Officer and Corporate Secretary at Confluent Health where he was a member of the Executive Leadership Team and a principal advisor on corporate strategy and innovation, mergers and acquisitions, corporate governance, private equity partnership, and corporate finance. Brooks is a veteran of Humana Inc. (DJIA: HUM) where he was Senior Vice President, Deputy General Counsel & Corporate Secretary, and Head of both the Corporate and Government Programs Law Groups. He also served separately as Chief Counsel and Chief Compliance Officer for all of Humana’s Medicare Advantage, Part D, Medicaid, Pharmacy, and PBM lines of business. Prior to Humana, he was an attorney for a large national law firm in Chicago representing health care organizations across the country. He is an active member of the national healthcare community where he is a regular speaker and contributor.

“Designing future care models requires an intentional innovation approach, which looks beyond provider solutions and instead considers point solutions, such as developing digital capabilities, accelerating value-based care, and developing new services, products, and partnerships to diversify revenue and enhance existing lines of business,” said Confluent Health’s CEO, Larry Benz, PT, DPT, OCS, MBA, FAPTA.

Benz further stated, “Innovation is something Confluent is highly invested in because we believe that access to low-cost, quality healthcare, digital therapeutics, and care innovations are truly essential to elevating patient care in every community. Confluent Health leadership is incredibly supportive of Confluent Innovation’s initiatives and its mission to be trailblazers in the digital health care space, and we believe Brooks’ appointment will help support and further amplify that mission.”

###

About Confluent Health:

Confluent Health is a family of physical and occupational therapy companies. We are transforming health care by strengthening private practices, developing highly effective clinicians, innovating new services and technology to improve the quality of care for patients, and lowering costs via more effective treatment, workplace wellness, and injury prevention. For more information, visit goconfluent.com or find us on Facebook, LinkedIn, and Twitter at @confluentfamily.

Share article on social media or email:

Join SGF physicians Dr. Amrane and Dr. Hayden for free, fertility events in honor of Pride and Men’s Health Month.

“We provide top-notch fertility care for our LGBTQ+ patients in a friendly, compassionate, and inclusive environment. LGBTQ+ couples and individuals receive equal access to SGF’s fertility services and financial offerings.”

ROCKVILLE, Md. (PRWEB)
June 06, 2022

Shady Grove Fertility (SGF) remains dedicated to its core mission of reaching and teaching the community about fertility health and options for overcoming infertility by offering free in-person seminars and virtual fertility webinar events in June, including events that recognize LGBTQ+ Pride and Men’s Health Month. Each event concludes with a question-and-answer session where attendees can get their questions answered by SGF’s physician experts.

To kick off June events, SGF New York physicians, Anate Brauer, M.D., Robert Setton, M.D., and Tomer Singer, M.D., will host an in-person fertility seminar at SGF’s Manhattan office on June 8 at 6:30 p.m. ET. The SGF New York physicians will guide information seekers through the first steps of beginning fertility treatment, followed by a Q&A session. Attendees may be eligible to receive a free consult.*

The following day, Selma Amrane, M.D., who sees patients at SGF’s Towson, Maryland office, will host the LGBTQ+ Family-Building webinar in honor of Pride Month on June 9 at noon ET. Dr. Amrane will share what to expect from SGF’s LGBTQ+ family-building services including:

• 
  The basic fertility work-up explained
• Treatment options for same-sex couples and transgender couples
• Legal considerations for LGBTQ+ family-building
• Financial programs at SGF to help make treatment more affordable

“At SGF, we believe everyone should be able to have the family of their dreams,” shares Dr. Amrane. “We provide top-notch fertility care for our LGBTQ+ patients in a friendly, compassionate, and inclusive environment. LGBTQ+ couples and individuals receive equal access to SGF’s fertility services and financial offerings.”

Information seekers in the Philadelphia metro area are invited to join SGF fertility specialists, Russell Hayden, M.D., Isaac Sasson, M.D., and Brianna Schumacher, M.D., for the in-person Chesterbrook Fertility seminar on June 21 at 5:30 p.m. ET as they review how infertility affects both male and female partners, followed by a Q&A session. Attendees may be eligible to receive a free consult.*

In honor of Men’s Health Month, Russell Hayden, M.D., a reproductive urologist at SGF’s Center for Male Fertility, will host a free Male Fertility webinar on June 29 at noon ET. Many people mistakenly believe that infertility is solely caused by the female partner. The reality is that 40 to 50 percent of all infertility cases are due to male factor infertility.

“One in 8 couples of reproductive age are facing infertility,” shares Dr. Hayden. “We want our patients to understand that infertility does not only affect women. We encourage men to seek answers to their fertility struggles and recommend that men are evaluated at the same time as their female partners when trying to conceive.”

June 2022 events at-a-glance:

• June 8 @ 6:30 p.m. ET | Manhattan Fertility seminar | Tomer Singer, M.D., Anate Brauer, M.D., and Robert Setton, M.D.
• June 9 @ 12 p.m. ET | LGBTQ+ Family Building webinar + Q&A | Selma Amrane, M.D.
• June 11 @ 8 a.m. ET | Race for the Family | Cade Foundation
• June 15 @ 12 p.m. ET | IVF webinar + Q&A | Matthew Connell, D.O.
• June 21 @ 5:30 p.m. ET | Chesterbrook Fertility seminar | Russell Hayden, M.D., Isaac Sasson, M.D., and Brianna Schumacher, M.D.
• June 22 @ 12 p.m. ET | Donor Egg Treatment webinar + Q&A | Valerie Libby, M.D.
• June 29 @ 12 p.m. ET | Male Fertility webinar + Q&A | Russell Hayden, M.D.

While SGF fertility webinars and seminars are free, interested parties must register to attend by visiting the SGF calendar of events. For more information about fertility, visit SGF’s growing resource library for free, on-demand webinars, E-books, and other education resources on topics such as endometriosis, PCOS, low-tech treatment options, weight and infertility, and much more.

Follow SGF on Facebook and Instagram for the latest updates, as more free events can be added to SGF’s monthly calendar of events

For people struggling to conceive, it may be time to consult a fertility specialist. Contact the SGF New Patient Center at 1-888-761-1967 or complete a brief online request form to schedule a virtual fertility consult with an SGF physician. A virtual physician consult is the first step toward pursuing a pregnancy with the help of SGF.

*See event page for exclusion and more information.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 46 locations, including new locations in Texas, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Share article on social media or email:

Farlong Nutraceutical is offering 20% off top-selling supplements including Brain Advanced Support, Astaxanthin and Bee Propolis through the end of June in honor of National Employee Wellness Month.

WALNUT, Calif. (PRWEB)
June 06, 2022

Farlong Nutraceutical, a vertically integrated, plant-based ingredient and supplement company, is offering 20% off top-selling supplements including Brain Advanced Support, Astaxanthin and Bee Propolis, through the end of June in honor of National Employee Wellness Month.

The challenges of career demands, coupled with stress, anxiety and daily work-life balance, often take a toll on both the physical and mental health of busy professionals. Farlong offers a number of proprietary formulas and supplements that can help optimize energy levels, promote cognitive health, and boost the immune system.

Farlong’s Brain Advanced Support contains Lifeflower® Erigeron Breviscapus extract, which helps to maintain healthy cognitive function by encouraging blood flow to the brain. The boost to blood circulation provided by this supplement can also benefit the cardiovascular system. The recommended dosage is one capsule daily with a meal.

Farlong’s Astaxanthin supports cardiovascular, brain and joint health including physical performance and stamina, anti-aging and UV protection. Astaxanthin is a carotenoid recognized as the strongest natural antioxidant which works to boost your immune system and provide anti-inflammatory effects. As a dietary supplement, Astaxanthin can be made into softgels, tablets, capsules or a liquid, and it can be added into foods and beverages.

Bee Propolis has been used extensively throughout history in both ancient Greece and China. Propolis is one of the most popular supplement foods in the market due to its efficacy and side-effect-free properties. Propolis contains a complex blend of biochemical elements including beewax, essential oils, vitamins, and bioflavonoids that work to strengthen the immune system. The recommended dosage is one capsule daily.

Farlong creates natural and herbal supplements to promote a healthy and natural life, focusing on top quality ingredients and ancient roots. The company provides contract manufacturing services and more than 400 unique ingredients for health and beauty brands to develop proprietary formulas and product lines, and also produces its own consumer line of natural supplements from seed to shelf. Farlong’s GAP certified farms are located in Yunnan Province, a geographical area known for harvesting specific medicinal herbs, proven to benefit the health and improvement for a variety of health conditions.

About Farlong Nutraceutical:

Farlong is a science-based and vertically integrated functional ingredient and formula provider who has more than 24 years of experience focusing on discovering, developing, and providing safe, effective, and unique medicinal herbs, plant extracts, and formulas with its own GAP (Good Agricultural Practice) certified cultivation base, cGMP (Current Good Manufacturing Practice) certified manufacturing facilities and distribution channels. Combining ancient Oriental medicine and modern technology, Farlong develops its own line of natural supplement brands, while offering contract manufacturing services and ingredients for health and beauty companies to create proprietary formulas and product lines. For more information, visit Farlong.com for supplements and 400+ ingredients, and follow on Facebook, Twitter and Instagram.

Share article on social media or email:

From insights to planning and media activation to optimization, Empower™ leverages consistent healthcare audience data.

“Custom-built and optimized over ten years, Empower™ fuels insight, orchestration and real-time activation across both audiences, and delivers exponential ROI from integrated media planning and connectivity,” said Jose Ferreira, EVP, Product Strategy & Transformation.

PHILADELPHIA (PRWEB)
June 06, 2022

CMI Media Group, leading media agency to healthcare’s game changers and a WPP company (NYSE: WPP), today celebrates the 10th anniversary of the industry-changing platform, Empower™. It is the industry’s first and only people-first precision and performance data platform that manages the complete marketing process. From insights to planning and media activation to optimization, Empower™ leverages consistent healthcare audience data.

“Empower™ is the only platform that ties strategy to addressable activation specific to individual HCPs and patients/caregivers on a one-to-one level at scale. Custom-built and optimized over ten years, it fuels insight, orchestration and real-time activation across both audiences, and delivers exponential ROI from integrated media planning and connectivity. For over a decade it has been the core of everything we do, and leveraged with success by over 50 clients. We’ve continued to innovate, infuse actionable data and AI, as well as develop functional capabilities within the platform that powerfully drive our industry forward and reach more of the decision makers that improve healthcare experiences for all,” said Jose Ferreira, EVP, Product Strategy & Transformation and one of the original designers of Empower™ when it was first developed.    

“We’ve been able to prove that consistent data drives effective and efficient media investment. We developed Empower™ to be a platform that combines the right technology, data management, and process to deliver excellence for our clients,” said Oleg Korenfeld, Chief Technology Officer. “Empower™ is the solution to ensure media strategy and activation are consistent and accurate. We were first to offer this for HCP audiences, first to offer for consumer audiences, and first to offer an omnichannel solution. Now we’re moving into the next phase of the platform by providing SaaS access for clients who choose to manage parts of the planning and activation process in-house. Empower™ remains a unique end-to-end offering.”

The Empower™ platform was launched in 2012 as an extension of ByDoctor®, which was created in 2002, under the company’s proprietary suite of services originally developed as a first of its kind platform helping to define HCP audiences. In 2020, ByDoctor® was officially renamed Empower™ to better encapsulate the full evolution of the platform with the power of enhanced precision planning and connectivity across HCP and consumer audiences, and the future forward advancement in SaaS for clients to gain access to the powerhouse suite of services. In the same year, the platform was industry recognized as a top innovation of the year by PM360.

“Empower™ has enabled us to make better, more meaningful connections between healthcare professionals, consumers, and the healthcare companies that are producing life-improving treatments. After ten years, the impact of this is jaw-dropping, and we continue to advance,” said Stan Woodland, Chairman of CMI Media Group. “Empower™ has enabled CMI Media Group to deliver over $900 million per year in incremental revenue to clients, while helping impact healthier lives of over 50,000,000 people.”

Empower™ allows CMI Media Group to close the loop on integrated consumer/HCP audience planning, messaging, and outreach, making every campaign more strategically data-driven, effective, and impactful. Becoming an industry staple since entering the market in 2002, Empower™ has fueled many industry firsts, including individualized affinity scoring, one-to-one personalization at scale, and the execution of performance based agile marketing​.

About CMI Media Group

CMI Media Group, a WPP company (NYSE: WPP, http://www.wpp.com), is a full-service media agency focused solely on health, wellness, and pharmaceutical marketing. CMI Media Group’s core offerings include Audience Strategy, Planning, Development, and Insights; Data and Analytics; Buying and Investment; and Direct Response and Customer Experience. As the leading media resource for the world’s top healthcare companies, CMI Media Group brings together leading technology, data, and talent to deliver seamless capabilities for clients. CMI Media Group has been recognized as a leader in DE&I, talent retention and employee development as well as one of the industry’s best places to work. To apply for a position within our teams visit https://www.cmimediagroup.com/careers

Share article on social media or email: